Transforming Real-World Evidence Generation in Gastroenterology: Century Health and AGA Join Forces

Introduction

The collaboration between Century Health and Arizona Gastrointestinal Associates (AGA) marks a pivotal moment in the field of gastroenterology research. With the landscapes of inflammatory bowel disease (IBD) and metabolic dysfunction-associated steatohepatitis (MASH) evolving rapidly, this partnership aims to bridge a significant gap in real-world clinical evidence and drug development.

What the Partnership Entails

Founded to leverage artificial intelligence for clinical research, Century Health is teaming up with AGA, an independent gastroenterology network, to curate and refine some of the most complex clinical data available. The goal is clear: convert unstructured medical data into structured datasets that will help in generating real-world evidence, ultimately benefiting patients suffering from IBD and MASH.

AGAs independence as a physician-led organization provides a unique advantage; they are on the front lines assessing how these diseases manifest in a community setting. This collaboration will assemble an invaluable dataset, significantly contributing to understanding treatment patterns and patient outcomes in these often-overlooked cases.

The Role of Artificial Intelligence

At the heart of this transformation is Century Health's data abstraction model called CHARM, which automates the process of organizing and analyzing fragmented clinical data. Traditionally, researchers have faced the daunting task of sifting through clinical notes and endoscopy reports, a process that is both labor-intensive and susceptible to human error. CHARM proficiently converts this messy, unstructured information into structured formats that aid in analysis and research.

This technological shift not only boosts the efficiency of converting data into research-ready formats but also liberates clinical staff from repetitive data management tasks, allowing them to concentrate more on patient care. As Dr. Vikram Singh of AGA stated, while they possess strong clinical insights, extracting meaningful data patterns has historically been cumbersome. This AI-powered approach will streamline that process.

Importance of Real-World Clinical Data

IBD and MASH are pressing health issues that can escalate into severe complications if not diagnosed and treated timely. Currently, there are over 23 therapies approved for IBD, yet no definitive cure exists. The treatment strategies are extremely personalized, with patients often encountering multiple medication lines before identifying an effective regime. Real-world data becomes essential here, as it reflects actual treatment experiences and patterns, vital for pharmaceutical developers to innovate effectively.

In recent years, the landscape of treatments for MASH has seen significant advancement, especially following the FDA's approval of a disease-modifying therapy. However, insights from everyday clinical practice have remained scarce. This partnership will fill that gap, providing invaluable real-world data that can guide future clinical trials and therapeutic advancements.

AGA’s Unique Position

Operating within the greater Phoenix area, AGA houses 25 board-certified gastroenterologists and two in-house pathologists. Their considerable scale allows them to gather and maintain rich datasets that are representative of actual patient conditions and treatment protocols. This broad clinical base places AGA at an advantageous focal point for the generation of consistent real-world evidence. "We're engaged daily with complex patient cases, and this collaboration lets us uncover significant patterns without overburdening our clinical teams," noted Vish Srivastava, Co-Founder and CEO of Century Health.

Conclusion

The undertaking between Century Health and Arizona Gastrointestinal Associates is set to redefine the landscape of gastroenterology research. By harnessing advanced AI technologies to transform vast amounts of unstructured clinical data, they are poised to significantly advance the understanding and treatment of IBD and MASH. Such innovations not only promise to enhance drug discovery processes but also ultimately aim to improve patient experiences and outcomes.

In summary, this collaboration represents a significant leap forward in bridging the gap between patient care and research, reinforcing the critical role that real-world evidence plays in the evolving field of gastrointestinal health.